A new way to deliver treatment for eye inflammation
Official title: DECON: A sustained topical delivery platform to treat ocular inflammation
Funded at University of Illinois at Chicago · NIH-11094875 · Data updated 2026-11-12
This study is working on a new eye treatment that can help kids and teens with eye infections and inflammation, making it easier for them to manage their condition by needing to use the medicine less often.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | September 30, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $398,369 |
| NIH project number | 5R01EY034508-03 |
| Project ID | NIH-11094875 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and adolescents experiencing ocular herpes or other forms of ocular inflammation.
✕Less likely to help
Patients with non-inflammatory eye conditions or those who do not respond to topical treatments may not benefit from this research.
What this research studies
This research focuses on developing a sustained topical delivery system to treat ocular inflammation, which is a leading cause of blindness. The approach aims to improve patient compliance by reducing the frequency of medication administration, particularly for conditions like ocular herpes that affect children and adolescents. By combining antimicrobial and anti-inflammatory treatments, the research seeks to provide a more effective and convenient option for managing eye infections and inflammation. Patients will receive a topical treatment that can help control both the infection and the resulting inflammation.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier-to-use treatments for patients suffering from ocular inflammation, potentially reducing the risk of blindness.
How similar studies have gone: Previous research has shown promise in developing sustained delivery systems for other conditions, suggesting potential success for this novel approach in ocular treatment.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Yadavalli, Tejabhiram — University of Illinois at Chicago
- Study coordinator: Yadavalli, Tejabhiram
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.